Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 5/20 | 0.60 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.60 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.60 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.60 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.60 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.60 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.60 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.60 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.60 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.60 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.60 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.60 |
| ▸ | KCND3 | Q9UK17 | 1/20 | 0.60 |
| ▸ | HHAT | Q5VTY9 | 3/20 | 0.58 |
| ▸ | PRCP | P42785 | 2/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.52 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.51 |
| ▸ | ESR1 | P03372 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1696394 | 1.00 | CHRM3 (0.60) | CHRM3CHRM2CHRM1CACNA1FCHRM4 | |
| SCHEMBL12046708 | 1.00 | CHRM3 (0.60) | CHRM3CHRM2CHRM1CACNA1FCHRM4 | |
| SCHEMBL13041647 | 1.00 | CHRM3 (0.60) | CHRM3CHRM2CHRM1CACNA1FCHRM4 | |
| SCHEMBL3073645 | 0.93 | HDAC3 (0.54) | CHRM3CHRM2CHRM1CACNA1FCHRM4 | |
| SCHEMBL7210566 | 0.92 | CHRM3 (0.52) | CHRM3CHRM2CHRM1CACNA1FCHRM4 | |
| SCHEMBL28066988 | 0.91 | CHRM3 (0.56) | CHRM3CHRM2CHRM1CACNA1FCHRM4 | |
| SCHEMBL7213954 | 0.90 | CHRM3 (0.62) | CHRM3CHRM2CHRM1CACNA1FCHRM4 | |
| SCHEMBL7209587 | 0.90 | TRPM8 (0.53) | CHRM3CHRM2CHRM1CACNA1FCHRM4 | |
| SCHEMBL22784241 | 0.90 | CHRM3 (0.62) | CHRM3CHRM2CHRM1CACNA1FCHRM4 | |
| SCHEMBL7209238 | 0.90 | CHRM3 (0.62) | CHRM3CHRM2CHRM1CACNA1FCHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099365-A1 | Processes for solifenacin preparation | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-04-16 | — | — | US | claimed |
| WO-2009011844-A1 | PROCESSES FOR SOLIFENACIN PREPARATION | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-01-22 | — | — | WO | claimed |
| CN-103787969-B | A kind of (1S)-1-phenyl-3,4-dihydro-2(1H) preparation method of-isoquinolinecarboxylic acid ester | 上海京新生物医药有限公司 | 2016-07-06 | — | — | CN | disclosed |
| US-9018379-B1 | Process of preparing solifenacin or salt thereof, and novel intermediate used in the process | KYUNG DONG PHARM. CO., LTD. (KR) | 2015-04-28 | — | — | US | disclosed |
| US-9018379-B1 | Process of preparing solifenacin or salt thereof, and novel intermediate used in the process | KYUNG DONG PHARM. CO., LTD. (KR) | 2015-04-28 | — | — | US | disclosed |
| US-20150112072-A1 | PROCESS OF PREPARING SOLIFENACIN OR SALT THEREOF, AND NOVEL INTERMEDIATE USED IN THE PROCESS | KYUNG DONG PHARM. CO., LTD. (KR) | 2015-04-23 | — | — | US | disclosed |
| US-20150112072-A1 | PROCESS OF PREPARING SOLIFENACIN OR SALT THEREOF, AND NOVEL INTERMEDIATE USED IN THE PROCESS | KYUNG DONG PHARM. CO., LTD. (KR) | 2015-04-23 | — | — | US | disclosed |
| US-20140228575-A1 | Process for the Preparation of Solifenacin and Salts Thereof | ISOCHEM (FR) | 2014-08-14 | — | — | US | disclosed |
| US-20140228575-A1 | Process for the Preparation of Solifenacin and Salts Thereof | ISOCHEM (FR) | 2014-08-14 | — | — | US | disclosed |
| US-8772491-B2 | Process for the preparation of solifenacin succinate | AUROBINDO PHARMA LTD (IN) | 2014-07-08 | — | — | US | disclosed |
| US-8772491-B2 | Process for the preparation of solifenacin succinate | AUROBINDO PHARMA LTD (IN) | 2014-07-08 | — | — | US | disclosed |
| WO-2008019055-A2 | PROCESSES FOR OPTICAL RESOLUTION OF 1-PHENYL-1,2,3,4-TETRAHYDROISOQUINOLINE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2008-02-14 | — | — | WO | disclosed |
| WO-2008011462-A2 | PROCESS FOR PREPARING SOLIFENACIN AND ITS SALTS | DR. REDDY'S LABORATORIES LTD. (IN) | 2008-01-24 | — | — | WO | disclosed |
| US-20070191425-A1 | Solifenacin-containing composition | ASTELLAS PHARMA INC. (JP) | 2007-08-16 | — | — | US | disclosed |
| US-20070191425-A1 | Solifenacin-containing composition | ASTELLAS PHARMA INC. (JP) | 2007-08-16 | — | — | US | disclosed |
| US-20070185329-A1 | Method for producing solifenacin or salts thereof | ASTELLAS PHARMA INC. | 2007-08-09 | — | — | US | disclosed |
| US-20070185329-A1 | Method for producing solifenacin or salts thereof | ASTELLAS PHARMA INC. | 2007-08-09 | — | — | US | disclosed |
| US-20070185329-A1 | Method for producing solifenacin or salts thereof | ASTELLAS PHARMA INC. | 2007-08-09 | — | — | US | disclosed |
| EP-1757604-A1 | PROCESS FOR PRODUCING SOLIFENACIN OR ITS SALT | Astellas Pharma Inc. (JP) | 2007-02-28 | — | — | EP | disclosed |
| EP-1757604-A1 | PROCESS FOR PRODUCING SOLIFENACIN OR ITS SALT | Astellas Pharma Inc. (JP) | 2007-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150112072-A1 | PROCESS OF PREPARING SOLIFENACIN OR SALT THEREOF, AND NOVEL INTERMEDIATE USED IN THE PROCESS | OSTC, NEU3, CHRNB3 | CHRM3 7/4885CHRM2 91/4885CHRM1 39/4885 |
| US-20070191425-A1 | Solifenacin-containing composition | ADRB3, CHRNA5, CHRNB3 | CHRM3 8/4885CHRM2 33/4885CHRM1 48/4885 |
| US-20070185329-A1 | Method for producing solifenacin or salts thereof | SUCNR1, GLS, CACNA1S | CHRM3 23/4885CHRM2 92/4885CHRM1 75/4885 |
| US-20140228575-A1 | Process for the Preparation of Solifenacin and Salts Thereof | NEU3, NEU4, ADRB3 | CHRM3 9/4885CHRM2 49/4885CHRM1 47/4885 |
| US-20090099365-A1 | Processes for solifenacin preparation | OPRK1, OPRL1, OPRD1 | CHRM3 20/4885CHRM2 37/4885CHRM1 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.